RxDoctor Payments Data

Gregory Almony, MD

Cardiovascular Disease · Ogden, UTNPI 1023003142

Payments from drug & device makers

$253in general payments, 2019–2025

Across 12 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$61
  • Regeneron Healthcare Solutions, Inc.$54
  • Abbott$46
  • Boston Scientific$21
  • Boehringer Ingelheim$19
  • Amarin Pharma, Inc.$19
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$253 in reported general payments places this provider in the 20th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$143,044
Medicare patients
1,085
Services billed
2,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban219$206,070
EntrestoSacubitril/Valsartan90$107,241
XareltoRivaroxaban70$71,720
JardianceEmpagliflozin73$48,883
FarxigaDapagliflozin Propanediol49$46,840
Repatha SyringeEvolocumab17$14,257
BrilintaTicagrelor20$10,435
Rosuvastatin Calcium514$7,040
Praluent PenAlirocumab13$6,655
Ezetimibe298$6,271
Ranolazine ErRanolazine40$5,695
Metoprolol Succinate338$4,230
Nitroglycerin234$2,933
Atorvastatin Calcium363$2,881
Isosorbide Mononitrate ErIsosorbide Mononitrate194$2,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$61$107,24190 claims
Boehringer IngelheimJardiance$19$48,88373 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →